secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYOMO, INC. (MYO)
CIK:        0001369290
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040584
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myomo Q2 revenue up 62% to $6.0M; net loss narrows to $1.0M
-----------------------------------------------------------

- Product revenue $4.2M (+15% YoY); revenue units 97 (+21%). Total revenue includes $1.7M JV license fee.
- Gross margin 71.8% vs 65.3%; net loss $1.0M ($0.04/sh) vs $2.9M loss ($0.42/sh) YoY.
- Patient pipeline 969 candidates (+27%); 408 new candidates added in Q2 (+57%).
- CMS proposed rule may expand brace definition to include MyoPro; Medicare Part B reimbursement anticipated in 6-12 months.
- Outlook: modest Q3 YoY growth; full-year product revenue growth target of 20-30% dependent on authorizations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/0000950170-23-040584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369290/000095017023040584/myo-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer